VolitionRx (NYSE:VNRX) Issues Quarterly Earnings Results

VolitionRx (NYSE:VNRX) posted its earnings results on Monday. The company reported ($0.11) EPS for the quarter, Zacks reports. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million.

VolitionRx Stock Performance

VNRX opened at $0.75 on Wednesday. The firm has a market cap of $59.00 million, a PE ratio of -1.47 and a beta of 1.38. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $1.00 and a 200-day simple moving average of $0.87. VolitionRx has a fifty-two week low of $0.55 and a fifty-two week high of $2.10.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. increased its position in shares of VolitionRx Limited (NYSE:VNRX) by 4.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 542,444 shares of the company’s stock after acquiring an additional 22,046 shares during the period. Vanguard Group Inc. owned about 0.69% of VolitionRx worth $374,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.